Application of butenafine in resisting mycobacterium abscessus infection

By developing the inhibitory effect of fentanyl on Mycobacterium abscessus, and preparing products in various dosage forms, the problem of the lack of effective treatment for drug-resistant Mycobacterium abscessus in existing technologies has been solved, and effective inhibition and treatment of Mycobacterium abscessus have been achieved.

CN118924715AActive Publication Date: 2024-11-12BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411250749.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-11-12
Estimated Expiration
2044-09-06

AI Technical Summary

Technical Problem

Current technology lacks effective drugs to combat drug-resistant Mycobacterium abscessus infection, leading to difficult treatment and severe side effects. Furthermore, existing antibiotics are not active enough against Mycobacterium abscessus.

Method used

Utilizing the antifungal activity of butenafine, its inhibitory effect on Mycobacterium abscessis was developed, and various dosage forms of medical and non-medical products, including tablets, capsules, and pellets, were prepared. Combined with pharmaceutically acceptable carriers and excipients, these products were used to inhibit and treat Mycobacterium abscessis infections.

Benefits of technology

Butenafine showed good antibacterial activity against both standard strains and clinical isolates of Mycobacterium abscessus, with an MIC of up to 2 μg/mL. The MIC of clinical isolates ranged from 0.5 to 8 μg/mL, providing a new treatment option and reducing the risk of drug resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005032170920000061
    Figure BDA0005032170920000061
  • Figure BDA0005032170920000062
    Figure BDA0005032170920000062
  • Figure BDA0005032170920000071
    Figure BDA0005032170920000071
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to application of butenafine in resisting mycobacterium abscessus infection. The butenafine has good bacteriostatic activity on standard strains and clinical isolates of the mycobacterium abscessus, the MIC (minimal inhibitory concentration) of the standard strains of the mycobacterium abscessus can reach 2 mu g / mL, and the MIC distribution of the clinical isolates of the mycobacterium abscessus is 0.5-8 mu g / mL. In the anti-mycobacterium abscessus infection, butenafine can become a new therapeutic drug.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and particularly relates to an application of butenafine in resisting mycobacterium abscessus infection. Background Art

[0002] Nontuberculous mycobacteria (NTM) refers to the general term for mycobacteria other than Mycobacterium tuberculosis complex and Mycobacterium leprae in the genus Mycobacterium. In previous epidemiological surveys on tuberculosis, it was found that the isolation rate of NTM continued to rise, accounting for as high as 22.9% in the 2010 survey (Zhou L, Xu D, Liu HC, Wan KL, Wang RB, Yang ZC. Trends in the Prevalence and Antibiotic Resistance of Non-tuberculous Mycobacteria in Mainland China, 2000-2019. Systematic Review and Meta-Analysis. Front Public Health. 2020, 8: 295.). According to the law of epidemiological development, as tuberculosis is gradually controlled in a country or region, the proportion of NTM disease in mycobacterium-related diseases will gradually increase. At present, in many countries, such as the United States and France, the number of people suffering from diseases caused by NTM has exceeded that of tuberculosis.

[0003] The pathogenicity and prevalence of different mycobacterial species vary significantly. Nearly 200 mycobacterial species have been reported, but only dozens of them are clinically pathogenic. A meta-analysis of the isolation composition of different NTM species showed that Mycobacterium abscessus (M.ab) accounted for 20.3% of all reported NTM and was the most common species among rapidly growing mycobacteria (RGM) (Yu X, Liu P, Liu G, Wang G, Chen S, Huang H. The Prevalence of Non-tuberculosis mycobacteria infections in mainland China: Systematic review and meta-analysis. J Infect. 2016, 73 (6): 558-567.). RGM are mostly saprophytes, mainly environmental mycobacteria, with weak pathogenicity, while Mycobacterium abscessus (M.ab) is a special case. Although M.ab infection mostly occurs in patients with underlying diseases, more than 30% of patients have normal immunity, indicating that unlike other NTM, M.ab has obvious pathogenicity. Mycobacterium abscessus mainly infects the lungs, followed by skin and soft tissue infections. There are often reports of skin ulcers caused by Mycobacterium abscessus that are persistent and unhealed. Diseases caused by Mycobacterium abscessus seriously threaten human health.

[0004] As the prevalence of M.ab infection increases year by year, it has also become an emerging health problem, and its drug resistance has been a long-term clinical challenge. Macrolide antibiotics including clarithromycin and azithromycin are the core drugs for the treatment of M. abscessus infection (Marion E, Song OR, Christophe T, et al. Mycobacterial Toxin Induces Analgesia in Buruli Ulcer by Targeting the Angiotensin Pathways [J]. Cell, 2014, 157 (7): 1565-1576.). However, in recent years, the resistance of M. abscessus to clarithromycin has become increasingly serious, with a reported resistance rate of 14% to 38% (Lee SH, Yoo HK, Kim SH, Koh WJ, Kim CK, Park YK, et al. The drug resistance profile of Mycobacterium abscessus group strains from Korea. Ann Lab Med. 2014; 34: 31-7.). The resistance of Mycobacterium abscessus to azithromycin is slightly lower than that to clarithromycin, with a resistance rate of about 10% (Shen Y, Wang X, Jin J, Wu J, Zhang X, Chen J, et al. In Vitro Susceptibility of Mycobacterium abscessus and Mycobacterium fortuitum Isolates to 30 Antibiotics. Biomed Res Int. 2018; 2018: 4902941.).

[0005] However, there is no specially developed drug for this type of Mycobacterium abscessus, which has a high isolation rate, strong pathogenicity and severe drug resistance. Therefore, the selection of clinical treatment drugs is usually based on the drugs used to treat tuberculosis. However, the side effects of antibiotics in the treatment of M.ab diseases are common and serious. Studies have found that cefoxitin is used to treat patients with M.ab lung disease, and adverse reactions frequently occur (Jeon K, Kwon OJ, Lee NY, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients [J]. American Journal of Respiratory and Critical Care Medicine, 2009, 180 (9): 896-902.). Long-term treatment with imipenem can also cause side effects such as neutropenia (Lopeman RC, Harrison J, Desai M, et al. Mycobacterium abscessus: environmental bacterium turned clinical nightmare [J]. Microorganisms, 2019, 7 (3): 90.). At present, all drugs in the Ma.ab treatment regimen recommended by the American Thoracic Society are derived from the expanded indications of drugs already on the market. Due to the difficulties in the development of original drugs, only bedaquiline, delamanid and premanid have been approved for marketing by the US Food and Drug Administration in the nearly half a century of research on tuberculosis. Therefore, fully exploring the anti-abscess mycobacterium abscessus activity of existing compounds or antibiotics is also an efficient way to develop anti-abscess mycobacterium abscessus drugs.

[0006] Butenafine is a broad-spectrum antifungal drug developed on the basis of naftifine. Its chemical structure and mode of action are similar to those of allylamine antifungal drugs. It has both antibacterial and bactericidal effects. Its antifungal activity is similar to or slightly stronger than that of naftifine and terbinafine. It also has a strong anti-inflammatory effect. Butenafine hydrochloride was developed by Japan Science and Technology Co., Ltd. and was launched in Japan in 1992. It is used externally to treat superficial fungal skin infections caused by dermatophytes. The new allylamine antifungal drugs inhibit squalene epoxidase, thereby blocking the synthesis of ergosterol in the fungal cell membrane, thereby leading to fungal cell death. At present, there are no reports on the inhibition of Mycobacterium abscessus by allylamine antifungal drugs. Summary of the invention

[0007] The present invention is completed based on the discovery that butenafine has the effect of inhibiting the activity of Mycobacterium abscessus.

[0008] In a first aspect, the present invention provides a use of butenafine in preparing a product for inhibiting Mycobacterium abscessus.

[0009] Furthermore, the Mycobacterium abscessus includes a standard strain of Mycobacterium abscessus, a clinical isolate of Mycobacterium abscessus, or Mycobacterium abscessus carried by a patient infected with Mycobacterium abscessus.

[0010] Furthermore, the product for inhibiting Mycobacterium abscessus includes a medical product or a non-medical product.

[0011] Furthermore, the medical product refers to medical drugs, and the non-medical product refers to experimental reagents or antibacterial agents.

[0012] Furthermore, one or more pharmaceutically acceptable carriers or excipients may be added to the product.

[0013] Furthermore, the carrier material includes, but is not limited to, one or more of a water-soluble carrier material, a poorly soluble carrier material and / or an enteric carrier material.

[0014] Furthermore, the water-soluble carrier material includes, but is not limited to, one or more of polyethylene glycol, polyvinyl pyrrolidone and / or organic acid.

[0015] Furthermore, the poorly soluble carrier material includes but is not limited to one or more of ethyl cellulose and / or cholesterol stearate.

[0016] Furthermore, the enteric carrier material includes but is not limited to one or more of cellulose acetate phthalate and / or carboxymethyl ethyl cellulose.

[0017] Furthermore, the product can be prepared into a variety of dosage forms, including but not limited to one or more of tablets, capsules, pellets, aerosols, pills, powders, solutions, suspensions, granules, liposomes, transdermal agents, buccal tablets, suppositories and / or lyophilized powder injections.

[0018] Furthermore, the preparation can be one or more of a conventional preparation, a sustained-release preparation, a controlled-release preparation and / or various microparticle delivery systems.

[0019] Furthermore, the tablets may widely use various carriers known in the art, including one or more of diluents and absorbents, wetting agents and binders, disintegrants, disintegration inhibitors, absorption promoters and / or lubricants.

[0020] Furthermore, the diluent and absorbent include, but are not limited to, one or more of starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, kaolin, microcrystalline cellulose and / or aluminum silicate.

[0021] Furthermore, the wetting agent and adhesive include, but are not limited to, one or more of water, glycerol, polyethylene glycol, ethanol, propanol, starch slurry, dextrin, syrup, honey, glucose solution, acacia gum slurry, gelatin slurry, sodium carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate and / or polyvinyl pyrrolidone.

[0022] Furthermore, the disintegrant includes, but is not limited to, one or more of dry starch, alginate, agar powder, brown algae starch, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene, sorbitan fatty acid ester, sodium dodecyl sulfate, methyl cellulose and / or ethyl cellulose.

[0023] Furthermore, the disintegration inhibitor includes but is not limited to sucrose, tristearin, cocoa butter and / or hydrogenated oil.

[0024] Furthermore, the absorption enhancer includes but is not limited to one or more of quaternary ammonium salts and / or sodium lauryl sulfate.

[0025] Furthermore, the lubricant includes, but is not limited to, one or more of talc, silicon dioxide, corn starch, stearate, boric acid, liquid paraffin and / or polyethylene glycol.

[0026] Furthermore, the tablets can be further made into coated tablets, including sugar-coated tablets, film-coated tablets, enteric-coated tablets, double-layer tablets and multi-layer tablets.

[0027] Furthermore, the pills may be prepared using a wide variety of carriers known in the art, including diluents and absorbents, binders and / or disintegrants.

[0028] Furthermore, the diluent and absorbent include, but are not limited to, one or more of glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinyl pyrrolidone, Gelucire, kaolin and / or talc.

[0029] Furthermore, the adhesive includes, but is not limited to, one or more of gum arabic, gum tragacanth, gelatin, ethanol, honey, liquid sugar, rice paste and / or batter.

[0030] Furthermore, the disintegrant includes, but is not limited to, one or more of agar powder, dry starch, alginate, sodium dodecyl sulfate, methyl cellulose and / or ethyl cellulose.

[0031] Furthermore, the suppository may be made of a wide variety of carriers known in the art, including but not limited to one or more of polyethylene glycol, lecithin, cocoa butter, higher alcohols, esters of higher alcohols, gelatin and / or semi-synthetic glycerides.

[0032] Furthermore, the injectable preparation includes, but is not limited to, one or more of a solution, a lyophilized powder injection and / or a suspension.

[0033] Furthermore, the injectable preparation may use all diluents commonly used in the art, including but not limited to one or more of water, ethanol, polyethylene glycol, 1,3-propylene glycol, ethoxylated isostearyl alcohol, polyoxygenated isostearyl alcohol and / or polyoxyethylene sorbitan fatty acid esters.

[0034] Furthermore, in order to prepare an isotonic injection solution, the injection preparation may be added with an appropriate amount of one or more of sodium chloride, glucose, glycerol, conventional cosolvents, buffers and / or pH regulators.

[0035] Furthermore, the various preparations may also add colorants, preservatives, spices, flavoring agents, sweeteners or other materials to the pharmaceutical preparations as needed.

[0036] In a second aspect, the present invention provides a use of butenafine in the preparation of a medicament for preventing and / or treating a disease caused by Mycobacterium abscessus infection, wherein the butenafine exerts its effect by inhibiting the activity of Mycobacterium abscessus.

[0037] Furthermore, the Mycobacterium abscessus includes a standard strain of Mycobacterium abscessus, a clinical isolate of Mycobacterium abscessus, or Mycobacterium abscessus carried by a patient infected with Mycobacterium abscessus.

[0038] Furthermore, one or more pharmaceutically acceptable carriers or excipients may be added to the drug for preventing and / or treating diseases caused by Mycobacterium abscessus infection.

[0039] Furthermore, the carrier material includes, but is not limited to, one or more of a water-soluble carrier material, a poorly soluble carrier material and / or an enteric carrier material.

[0040] Furthermore, the drug for preventing and / or treating diseases caused by Mycobacterium tuberculosis infection can be prepared into a variety of dosage forms, including but not limited to one or more of tablets, capsules, pellets, aerosols, pills, powders, solutions, suspensions, granules, liposomes, transdermal agents, buccal tablets, suppositories and / or lyophilized powder injections.

[0041] Furthermore, the preparation can be one or more of a conventional preparation, a sustained-release preparation, a controlled-release preparation and / or various microparticle delivery systems.

[0042] Furthermore, the various preparations may also add colorants, preservatives, spices, flavoring agents, sweeteners or other materials to the pharmaceutical preparations as needed.

[0043] Furthermore, the drug for preventing and / or treating diseases caused by Mycobacterium abscessus infection can be administered via injection, cavity administration, respiratory tract administration or mucosal administration.

[0044] Furthermore, the injection administration includes subcutaneous injection, intravenous injection, intramuscular injection and intracavitary injection, etc.

[0045] In a third aspect, the present invention provides a pharmaceutical composition comprising butenafine and another drug for preventing Mycobacterium abscessus infection.

[0046] The pharmaceutical composition has at least one of the following effects:

[0047] a) inhibiting the activity of Mycobacterium abscessus;

[0048] b) Anti-Mycobacterium abscessus infection;

[0049] c) prevention and / or treatment of diseases caused by Mycobacterium abscessus.

[0050] Furthermore, the Mycobacterium abscessus includes a standard strain of Mycobacterium abscessus, a clinical isolate of Mycobacterium abscessus, or Mycobacterium abscessus carried by a patient infected with Mycobacterium abscessus.

[0051] Furthermore, the lowest concentration of the pharmaceutical composition is no less than the minimum inhibitory concentration (MIC) of Mycobacterium abscessus that it inhibits.

[0052] Furthermore, the another anti-Mycobacterium abscessus infection drug includes one or more of antibiotics and other drugs that can help inhibit or kill Mycobacterium abscessus or improve the patient's resistance.

[0053] Furthermore, the antibiotics include one or more of rifampicin, streptomycin, ethambutol, moxifloxacin, clarithromycin and / or amikacin; and the other drugs include one or more of vitamins, amino acids, proteins and / or minerals.

[0054] Furthermore, one or more pharmaceutically acceptable carriers may be added to the pharmaceutical composition.

[0055] Furthermore, the pharmaceutical composition can be prepared into various forms such as injection, tablet, powder, granule, capsule, oral solution or pharmaceutical excipients; the above various dosage forms of drugs can be prepared according to conventional methods in the pharmaceutical field.

[0056] Furthermore, the pharmaceutical composition can be introduced into the body such as muscle, intradermal, subcutaneous, intravenous or mucosal tissue by injection, penetration, absorption, physical or chemical mediation; or can be introduced into the body after being mixed or encapsulated with other substances.

[0057] Beneficial Effects

[0058] Butenafine has good antibacterial activity against both standard strains and clinical isolates of Mycobacterium abscessus. The MIC for standard strains of Mycobacterium abscessus can reach 2μg / mL, while the MIC for clinical isolates of Mycobacterium abscessus is distributed between 0.5-8μg / mL.

[0059] Butenafine may be a new therapeutic drug against Mycobacterium abscessus infection. BRIEF DESCRIPTION OF THE DRAWINGS

[0060] Figure 1 MIC distribution of butenafine against clinical isolates of Mycobacterium abscessus. DETAILED DESCRIPTION

[0061] The specific embodiments of the present invention are further described below. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention. In addition, the technical features involved in the embodiments described below can be combined with each other as long as they do not conflict with each other.

[0062] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are commercially available unless otherwise specified.

[0063] Material Description

[0064] 1. McFarland turbidimetric tube

[0065] McFarland turbidimetric tube is a standard turbidity tube of different turbidity invented by McFarland for microbial turbidity measurement. It is prepared according to the ratio of sulfuric acid and barium chloride, as follows:

[0066]

[0067] 2. Test strains and drugs

[0068] Mycobacterium abscessus standard strain: ATCC 19977.

[0069] Butenafine: Molecular formula: C 23 H 27 N; the structural formula is as follows:

[0070]

[0071] Butenafine hydrochloride: purchased from MedchemExpress, CAS number 101827-46-7; molecular formula C 23 H 27 N·HCl, the structural formula is as follows:

[0072]

[0073] 3. Conversion of experimental drugs

[0074] The molecular weight of Butenafine Hydrochloride is 353.93 g / mol, wherein the molecular weight of the hydrochloric acid root is 35.45 g / mol. The potency of Butenafine in Butenafine Hydrochloride is calculated to be 90% (353.93 g / mol-35.45 g / mol / 353.93 g / mol=89.98%). According to the calculated potency, weigh 14.22 mg of Butenafine Hydrochloride (butenafine content is 12.8 mg), add 1 ml of DMSO, and prepare a drug stock solution with a final concentration of 12.8 mg / ml. Dilute to a working solution with a concentration of 128 μg / ml at a ratio of 1:100.

[0075] Example 1 Detection of antibacterial activity of butenafine against standard strains of Mycobacterium abscessus

[0076] 1.1 Preparation of standard strain suspension of Mycobacterium abscessus

[0077] The standard strain of Mycobacterium abscessus (ATCC19977) was inoculated into MH medium, cultured to the logarithmic growth phase, and turbidity was measured to 0.5 McFarland turbidimetric tube turbidity. It was diluted 1:200 and set aside.

[0078] 1.2 Minimum inhibitory concentration (MIC)

[0079] (1) Add 100 μl of Mueller Hinton (MH) medium to a 96-well plate;

[0080] (2) Add serially diluted drugs to columns 1 to 11;

[0081] (3) Add the diluted Mycobacterium abscessus standard strain suspension to columns 1-11 so that the final concentration of the suspension is 4×10 5 CFU / mL;

[0082] The final drug concentration in each well is shown in Table 1 , culture;

[0083] (4) Add 30 μl of resazurin colorimetric solution and observe the color change of the plate after incubation;

[0084] (5) Read the minimum inhibitory concentration (MIC).

[0085] Table 1. Drug concentration of butenafine

[0086]

[0087] MIC reading method: MIC is the drug concentration that can inhibit 90% of the colony growth. Blue wells are sterile growth, pink wells are bacterial growth, and the lowest drug concentration that prevents the color from changing from blue to pink is recorded as the MIC that can inhibit bacterial growth.

[0088] The positive control is a culture medium containing bacteria without drugs, i.e. column 12; another 96-well plate is added with a culture medium without drugs and bacteria, i.e. the negative control. When the positive control is pink and the negative control is blue, the MIC data of the batch is valid.

[0089] 1.3 Test results

[0090] The MIC of butenafine against the standard strain of Mycobacterium abscessus was 2 μg / mL.

[0091] Example 2 Detection of antibacterial activity of butenafine against clinically isolated Mycobacterium abscessus strains

[0092] 2.1 Test samples and methods

[0093] Clinical isolates: 39 strains isolated and cultured from sputum specimens of patients infected with Mycobacterium abscessus were identified as Mycobacterium abscessus by sequencing of 16SrRNA, hsp65, rpoB, and 16-23S rRNA intergenic region.

[0094] According to the method in Example 1, the in vitro antibacterial activity of butenafine against 39 clinical isolates of Mycobacterium abscessus was detected.

[0095] 2.2 Test results

[0096] The MIC results of butenafine against clinical isolates of Mycobacterium abscessus are shown in Table 2 .

[0097] Butenafine has good antibacterial activity against Mycobacterium abscessus, and its MIC can reach 0.5μg / mL at best.

[0098] MIC 50 and MIC 90 4μg / mL and 8μg / mL respectively.

[0099] Table 2 MIC of butenafine against clinical isolates of Mycobacterium abscessus

[0100]

[0101]

[0102]

Claims

1. An application of butenafine in preparing a product for inhibiting Mycobacterium abscessus.

2. Use of butenafine in the preparation of a medicament for preventing and / or treating diseases caused by Mycobacterium abscessus infection, wherein the butenafine exerts its effect by inhibiting the activity of Mycobacterium abscessus.

3. A pharmaceutical composition comprising butenafine and another drug for treating Mycobacterium abscessus infection, wherein the pharmaceutical composition has at least one of the following effects: a) inhibiting the activity of Mycobacterium abscessus; b) Anti-Mycobacterium abscessus infection; c) prevention and / or treatment of diseases caused by Mycobacterium abscessus.

4. The product for inhibiting Mycobacterium abscessus as claimed in claim 1 comprises a medical product or a non-medical product; the medical product refers to a medical drug; the non-medical product refers to an experimental reagent or an antibacterial agent.

5. One or more pharmaceutically acceptable carriers or excipients may also be added to the product as claimed in claim 1.

6. The drug for preventing and / or treating diseases caused by Mycobacterium abscessus infection as claimed in claim 2 may further contain one or more pharmaceutically acceptable carriers or excipients.

7. The lowest concentration of the pharmaceutical composition according to claim 3 is not lower than the minimum inhibitory concentration (MIC) of Mycobacterium abscessus that it inhibits.

8. Another anti-Mycobacterium abscessus infection drug as claimed in claim 3, comprising one or more of antibiotics and other drugs that can help inhibit or kill Mycobacterium abscessus or improve the patient's resistance.

9. One or more pharmaceutically acceptable carriers may also be added to the pharmaceutical composition.

10. The Mycobacterium abscessus according to claims 1 to 3, comprising a standard strain of Mycobacterium abscessus, a clinical isolate of Mycobacterium abscessus, or Mycobacterium abscessus carried by a patient infected with Mycobacterium abscessus.

Citation Information

Patent Citations

  • Discovery of F-ATP synthase inhibitors for treatment of mycobacterium abscessus diseases

    CN117858708A

  • Application of heterocyclic compound in resisting mycobacterium abscessus

    CN117860759A

  • ACC inhibitors for use in treating mycobacterial diseases

    US20190307760A1